Spots Global Cancer Trial Database for AZD1152 in Patients With Advanced Solid Malignancies-Study 3
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AZD1152 in Patients With Advanced Solid Malignancies-Study 3
Official Title: A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
Study ID: NCT00497679
Conditions
Interventions
Study Description
Brief Summary: The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Manchester, , United Kingdom
Research Site, Newcastle, , United Kingdom
Research Site, Oxford, , United Kingdom
Contact Details
Name: David Kerr, MD
Affiliation: University of Oxford
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
